Regeneron Pharmaceuticals will repurchase about $5 billion of the U.S. drugmaker’s shares directly from France’s Sanofi, without altering their 17-year partnership.
Sumitomo Dainippon Pharma and Roivant Sciences Create Broad Strategic Alliance for New Medicines
Alliances, Biopharmaceutical, Business, Drug Distribution, Market Access, Market exclusivity, New Medicines, Pediatric Rare Diseases, Prostate Cancer, Respiratory Disease, Stakes, Urinary Diseases, Women’s HealthThe Sumitomo Dainippon-Roivant Alliance encompasses up to 11 biopharmaceutical Vants with more than 25 innovative clinical programs and multiple potential product launches from 2020 to 2022, and access to key elements of Roivant’s proprietary technology platforms including DrugOme and Digital Innovation.